BACKGROUND AND OBJECTIVES: Bilirubin is a protective factor with antioxidant and anti-inflammatory properties, but its association with clinical outcomes of hemodialysis patients is unknown. Bilirubin degradation is mainly determined by the activity of hepatic bilirubin uridine diphosphate-glucuronosyltransferase (UGT1A1), which is significantly influenced by a TA-repeat polymorphism in the gene's promoter, an allele designated UGT1A1*28. The study aimed to clarify the association between serum bilirubin and UGT1A1*28 polymorphism and their respective effect on outcomes of chronic hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The cohort study comprised 661 chronic hemodialysis patients who were prospectively followed for 12 years. The endpoints were cardiovascular events (CVEs) and all-cause mortality. RESULTS: After adjustment for traditional and dialysis-related risk factors, individuals with bilirubin in the upper tertile had an adjusted hazard ratio of 0.32 for CVEs and 0.48 for all-cause mortality compared with those in the lower tertile. Individuals homozygous for UGT1A1*28 (genotype 7/7) had significantly higher bilirubin levels than those with 6/6 and 7/6 genotypes. In the same multivariable-adjusted model, individuals with 7/7 had approximately one tenth the risk for CVEs and one fourth the risk for all-cause mortality as compared with carriers of the 6 allele. CONCLUSIONS: A graded, reverse association was noted between serum bilirubin and adverse outcomes among chronic hemodialysis patients. Moreover, the UGT1A1*28 polymorphism had strong effects on bilirubin levels and the 7/7 genotype might have an important effect on reducing CVEs and death.
BACKGROUND AND OBJECTIVES:Bilirubin is a protective factor with antioxidant and anti-inflammatory properties, but its association with clinical outcomes of hemodialysis patients is unknown. Bilirubin degradation is mainly determined by the activity of hepatic bilirubin uridine diphosphate-glucuronosyltransferase (UGT1A1), which is significantly influenced by a TA-repeat polymorphism in the gene's promoter, an allele designated UGT1A1*28. The study aimed to clarify the association between serum bilirubin and UGT1A1*28 polymorphism and their respective effect on outcomes of chronic hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The cohort study comprised 661 chronic hemodialysis patients who were prospectively followed for 12 years. The endpoints were cardiovascular events (CVEs) and all-cause mortality. RESULTS: After adjustment for traditional and dialysis-related risk factors, individuals with bilirubin in the upper tertile had an adjusted hazard ratio of 0.32 for CVEs and 0.48 for all-cause mortality compared with those in the lower tertile. Individuals homozygous for UGT1A1*28 (genotype 7/7) had significantly higher bilirubin levels than those with 6/6 and 7/6 genotypes. In the same multivariable-adjusted model, individuals with 7/7 had approximately one tenth the risk for CVEs and one fourth the risk for all-cause mortality as compared with carriers of the 6 allele. CONCLUSIONS: A graded, reverse association was noted between serum bilirubin and adverse outcomes among chronic hemodialysis patients. Moreover, the UGT1A1*28 polymorphism had strong effects on bilirubin levels and the 7/7 genotype might have an important effect on reducing CVEs and death.
Authors: Jing-Ping Lin; L Adrienne Cupples; Peter W F Wilson; Nancy Heard-Costa; Christopher J O'Donnell Journal: Am J Hum Genet Date: 2003-02-28 Impact factor: 11.025
Authors: Piter J Bosma; Irene M van der Meer; Conny T Bakker; Albert Hofman; Marianne Paul-Abrahamse; Jacqueline C Witteman Journal: Clin Chem Date: 2003-07 Impact factor: 8.327
Authors: Florian Kronenberg; Hilary Coon; Alexander Gutin; Victor Abkevich; Mark E Samuels; Dennis G Ballinger; Paul N Hopkins; Steven C Hunt Journal: Eur J Hum Genet Date: 2002-09 Impact factor: 4.246
Authors: Libor Vítek; Milan Jirsa; Marie Brodanová; Milan Kalab; Zdenek Marecek; Vilém Danzig; Ladislav Novotný; Petr Kotal Journal: Atherosclerosis Date: 2002-02 Impact factor: 5.162
Authors: G Clermont; S Lecour; J Lahet; P Siohan; C Vergely; D Chevet; G Rifle; L Rochette Journal: Cardiovasc Res Date: 2000-08-18 Impact factor: 10.787
Authors: A Premawardhena; C A Fisher; Y T Liu; I C Verma; S de Silva; M Arambepola; J B Clegg; D J Weatherall Journal: Blood Cells Mol Dis Date: 2003 Jul-Aug Impact factor: 3.039
Authors: Dinanda J de Jager; Diana C Grootendorst; Kitty J Jager; Paul C van Dijk; Lonneke M J Tomas; David Ansell; Frederic Collart; Patrik Finne; James G Heaf; Johan De Meester; Jack F M Wetzels; Frits R Rosendaal; Friedo W Dekker Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez Journal: Exp Ther Med Date: 2018-05-18 Impact factor: 2.447
Authors: Ai-Ching Boon; Alfred K Lam; Vinod Gopalan; Iris F Benzie; David Briskey; Jeff S Coombes; Robert G Fassett; Andrew C Bulmer Journal: Sci Rep Date: 2015-10-26 Impact factor: 4.379
Authors: Jung Pyo Lee; Do Hyoung Kim; Seung Hee Yang; Jin Ho Hwang; Jung Nam An; Sang Il Min; Jongwon Ha; Yun Kyu Oh; Yon Su Kim; Chun Soo Lim Journal: PLoS One Date: 2014-04-01 Impact factor: 3.240
Authors: Kwok-Leung Ong; Matthew A Allison; Bernard M Y Cheung; Ben J Wu; Philip J Barter; Kerry-Anne Rye Journal: PLoS One Date: 2014-04-11 Impact factor: 3.240